MMSI Merit Medical Systems Inc.

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

Unique band provides precise placement and clear visibility of the access site, optimizing hemostasis for radial artery procedures

SOUTH JORDAN, Utah, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the PreludeSYNC EZ™ Radial Compression Device.

The new device is the latest in Merit’s ongoing excellence and leadership in advancing transradial access for endovascular patient care. It complements a robust radial portfolio of products that includes the Prelude IDeal™, Merit’s thin-walled hydrophilic sheath introducer with superior kink and compression resistance.1

Designed for optimal clinical performance, the PreludeSYNC EZ assists in achieving access site patent hemostasis (the prevention of bleeding) following radial artery access procedures.

A unique cinch-style wrist band supports controlled and precise two-handed placement, a key feature that differentiates it from other radial compression devices on the market. A large window provides clear visibility designed to further help with precise placement. Created with the patient and clinician in mind,​ the PreludeSYNC EZ provides a simplified alternative to the two-strap compression band currently on the market.

Radial artery access is a minimally invasive approach to diagnosing and treating a wide range of conditions. Through a pinhole-size site in the wrist, a catheter is inserted into the radial artery. Under imaging guidance, the catheter is then threaded through the body’s network of blood vessels to the location needing treatment.

The rate of radial artery access use in the United States is on the rise. Between 2011 and 2018, radial access for diagnostic angiograms (X-ray procedures that show blocked or narrowed vessels in the heart) increased from 17.5% to 60.4%.2 Radial access rates for percutaneous coronary intervention (procedures used to open blocked vessels) also grew from 14.0% to 51.8%.2 Radial coronary angiography and PCI have been linked to better clinical outcomes. 3 Benefits include fewer bleeding complications, improved patient comfort, and decreased procedure costs compared to femoral procedures, or those performed through the femoral artery in the groin.3

“Merit Medical is fully invested in being a leader in radial artery access,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “By listening to physician feedback, we transformed clinical needs into an advanced compression device that complements our expansive portfolio of solutions designed to support radial artery access procedures and deliver better patient care.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 500 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

|

  1. Data on File.



  2. Doll JA et al. 2022. “Trends in Arterial Access Site Selection and Bleeding Outcomes Following Coronary Procedures, 2011-2018.” Circ Cardiovasc Qual Outcomes (Mar 11). doi: 10.1161/CIRCOUTCOMES.121.008359. PMID: 35272504.



  3. O’Riordan. 2022. “Radial Access for Angiography and PCI on the Rise in the US.” TCTMD (Mar 16).



 



EN
21/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announ...

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She prev...

 PRESS RELEASE

Merit Medical to Participate at the J.P. Morgan Healthcare Conference

Merit Medical to Participate at the J.P. Morgan Healthcare Conference SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit  Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, Ja...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Provides Update on U.S. Reimbursement and Commercial Str...

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further conside...

 PRESS RELEASE

Merit Medical Releases 24-Month Efficacy Results from the Randomized A...

Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch